Tigermed and WuXi Biologics took part in the biopharmaceutical company's series D round, which will accelerate the development of its immuno-oncology drug candidates.

Adlai Nortye, a China-based developer of cancer treatments, has raised $100m in a series D round co-led by Tigermed and investment firm CMG-SDIC Capital, DealStreetAsia reported on Tuesday.

The round was also backed by Legend Star, a corporate venture capital subsidiary of conglomerate Legend Holdings, as well as contract pharmaceutical manufacturer WuXi Biologics’ industry fund.

Adlai Nortye is working on immuno-oncology treatments for cancer, and its pipeline of clinical-stage drug candidates includes Reolysin, an intravenously delivered immuno-oncolytic virus (IOV) being developed to treat solid tumors.

The company had already received nearly $100m in a series C round co-led by Tigermed and Yingke PE in September 2020, according to press reports.

The September round also featured ATCG Holdings, Shengxin Venture Capital, Puxin Ruiyuan, Hongtu and ICBC Asset Management, a division of financial services firm Industrial and Commercial Bank of China.

Adlai Nortye had previously secured $53m in a 2018 series B round featuring YuanMing Capital, Matrix Partners China, DT Capital Partners and Yahui Precision Medicine Fund.